A Phase 1 Trial of 8-Chloro-Adenosine in Combination With Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The ongoing Phase 1 trial of 8-Chloro-Adenosine in combination with Venetoclax targets relapsed/refractory acute myeloid leukemia (AML), a significant unmet medical need in oncology. The combination therapy aims to enhance anti-leukemia activity while establishing safety and tolerability. Given the competitive landscape, with several BCL-2 inhibitors already in the market, successful outcomes could position this combination as a novel treatment option, potentially leading to market differentiation. The collaboration with the National Cancer Institute (NCI) may enhance credibility and facilitate regulatory pathways. Investors should monitor enrollment rates and preliminary efficacy data closely, as these will influence future funding and partnership opportunities.
Indication: Acute Myeloid Leukemia
Modality: small molecule
Target: B-cell lymphoma-2 (BCL-2) protein and potential downstream signaling pathways involved in acute myeloid leukemia (AML) cell survival and proliferation.
Sponsor: City of Hope Medical Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 07, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: B-cell lymphoma-2 (BCL-2) protein and potential downstream signaling pathways involved in acute myeloid leukemia (AML) cell survival and proliferation.
View original source fields
Condition raw: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Condition normalized: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: B-cell lymphoma-2 (BCL-2) protein and potential downstream signaling pathways involved in acute myeloid leukemia (AML) cell survival and proliferation.
Target normalized: B-cell lymphoma-2 (BCL-2) protein and potential downstream signaling pathways involved in acute myeloid leukemia (AML) cell survival and proliferation.